Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...

Scientists are linking 2026's record-shattering tornado season directly to climate change, citing a Gulf of Mexico running three degrees above historical averages that is supercharging atmospheric ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

ABILENE, Texas — According to a recent Bloomberg report, more than half of the data centers slated for development across the United States this year are projected to be delayed. The constraint stems ...

David Pogue is a six-time Emmy winner for his stories on "CBS Sunday Morning," where he's been a correspondent since 2002. Pogue hosts the CBS News podcast "Unsung Science." He's also a New York Times ...

Protein engineering is a field primed for artificial intelligence research. Each protein is made up of amino acids; to optimize a protein function, researchers modify proteins by switching out one of ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. If you've built up a stash of airline points or miles, now is the time to use them for your next ...

Wisconsin is becoming a popular location for data centers due to its climate, water access, and affordable land. The majority of a data center's water footprint comes from the offsite electricity ...

Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...